| Eosinophilic granulomatosis with polyangiitis
Fasenra vs Nucala
Side-by-side clinical, coverage, and cost comparison for eosinophilic granulomatosis with polyangiitis.Deep comparison between: Fasenra vs Nucala with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNucala has a higher rate of injection site reactions vs Fasenra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucala but not Fasenra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fasenra
Nucala
At A Glance
SC injection
Every 4-8 weeks
IL-5 receptor alpha antagonist
SC injection
Every 4 weeks
IL-5 antagonist
Indications
- Asthmatic pulmonary eosinophilia
- Eosinophilic granulomatosis with polyangiitis
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
Dosing
Asthmatic pulmonary eosinophilia Adults and adolescents >=12 years: 30 mg SC every 4 weeks for first 3 doses, then every 8 weeks; pediatric 6-11 years weighing <35 kg: 10 mg SC every 4 weeks for first 3 doses, then every 8 weeks; pediatric 6-11 years weighing >=35 kg: 30 mg SC every 4 weeks for first 3 doses, then every 8 weeks.
Eosinophilic granulomatosis with polyangiitis 30 mg SC once every 4 weeks.
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Contraindications
- Known hypersensitivity to benralizumab or any of its excipients
- History of hypersensitivity to mepolizumab or excipients in the formulation
Adverse Reactions
Most common (>=3%) Headache, pyrexia, pharyngitis, hypersensitivity reactions (urticaria, rash)
Postmarketing Hypersensitivity reactions, including anaphylaxis
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Pharmacology
IL-5 receptor alpha antagonist; benralizumab is a humanized afucosylated IgG1 monoclonal antibody that binds the IL-5 receptor alpha subunit on eosinophils and basophils, inducing apoptosis via antibody-dependent cell-mediated cytotoxicity (ADCC) through NK cell Fc-gamma-RIII engagement.
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fasenra
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Fasenra
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (0/8)
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Fasenra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FasenraView full Fasenra profile
NucalaView full Nucala profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.